BRISTOL MYERS SQUIBB CO
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $12.97B | $1.62 | $2.04 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $11.50B | $1.31 | $1.58 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 5, 2026 | Before market open | $12.50B | $0.53 | $1.26 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $12.20B | $1.08 | $1.63 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $12.30B | $0.64 | $1.46 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | Before market open | $11.20B | $1.20 | $1.80 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 6, 2025 | Before market open | $12.34B | $0.04 | $1.67 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $11.90B | $0.60 | $1.80 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 26, 2024 | Before market open | $12.20B | $0.83 | $2.07 |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 25, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 2, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Diluted EPSnon-GAAP | 2026 | $6.75 to $7.00 | Raised |
| Gross Margin %non-GAAP | 2026 | 69% to 70% | Maintained |
| 2026 WW Revenue Growth | 2026 | 20% to 25% growth | New |
| Operating Expensesnon-GAAP | 2026 | $16.50B | Raised |
| Other income/(expense)non-GAAP | 2026 | -$700.00M | Lowered |
| Total Revenues (Reported & Ex-FX)non-GAAP | 2026 | $49.00B to $50.00B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Bristol Myers Squibb filed with the SEC
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 30, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 30, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 30, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 30, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 5, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 5, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INVESTOR PRESENTATION OF BRISTOL-MYERS SQUIBB COMPANY
Regulation FD disclosure · EX-99.1 to Form 8-K
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Other events · EX-99.1 to Form 8-K
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Other events · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 30, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 30, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 31, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 31, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 24, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 24, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 6, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 6, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
43rd Annual J.P. Morgan Healthcare Conference January 13th, 2025 Christopher
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 31, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 31, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 26, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 26, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 25, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 25, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,
Other events · EX-99.1 to Form 8-K
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 2, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 2, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INVESTOR PRESENTATION OF BRISTOL-MYERS SQUIBB COMPANY
Regulation FD disclosure · EX-99.1 to Form 8-K
JOINT PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY AND KARUNA THERAPEUTICS, INC.
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 26, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 26, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2023 Results July 27, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 27, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 27, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 2, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
QUARTERLY TREND ANALYSIS OF REVENUES
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 2, 2023
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K